<DOC>
	<DOC>NCT02572219</DOC>
	<brief_summary>Aim of this randomized, double-blind clinical study is to evaluate the efficacy of a nutraceutical preparation on early markers of cognitive impairment, in patients affected by arterial hypertension.</brief_summary>
	<brief_title>Effects of a Nutraceutical Preparation on Cognitive Impairment in Hypertensive Patients</brief_title>
	<detailed_description />
	<mesh_term>Cognition Disorders</mesh_term>
	<criteria>Written informed consent; Males or females between 40 and 65 years of age; Hypertensive patients classified according to their SBP (Systolic Blood Pressure) and DBP (Diastolic Blood Pressure) values. Included patients will be those with stage 1 hypertension (SBP 140159 mmHg; DBP 9099 mmHg) and with stage 2 hypertension (SBP 160179 mmHg; DBP 100109 mmHg). Previous acute myocardial infarction (AMI); Previous stroke and/or transient ischemic attack (TIA); Diabetes mellitus; History of atrial fibrillation or other severe arrhythmias; Severe cardiovascular diseases; Renal pathologies (creatinine &gt; 1.4 mg/dL); Preexisting psychiatric pathologies; Neurodegenerative diseases, such as multiple sclerosis, lateral amyotrophic sclerosis, Parkinson, Alzheimer, neuromuscular pathologies, epilepsy; Diagnosis of dementia; Depression; Longterm regular use of anxiolytics drugs, antidepressant drugs, antipsychotic drugs, hypnoinducing drugs, cognitive stimulators.</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>